AKBA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Akebia Therapeutics Inc (AKBA) is not a strong buy at the moment for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The stock shows mixed signals with no immediate positive catalysts or strong proprietary trading signals. While the company's revenue growth is promising, the significant drop in net income and EPS, along with bearish technical indicators, suggests that the stock lacks a strong entry point currently.
The MACD is slightly positive and expanding, indicating mild bullish momentum. However, the RSI is neutral at 55.877, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock price is below key resistance levels, with support at 1.317 and resistance at 1.447. Overall, the technical indicators suggest a weak trend.
Revenue increased by 23.93% YoY in Q4 2025, and gross margin improved significantly to 82.06%, up 41.56% YoY.
Net income dropped by 46.31% YoY, and EPS declined by 50.00% YoY. Analysts have lowered their price targets recently, citing lower-than-expected revenue and inventory challenges. No recent news or significant insider/hedge fund activity to support a bullish case.
In Q4 2025, revenue grew to $57.62M (+23.93% YoY), but net income dropped to -$12.24M (-46.31% YoY) and EPS fell to -0.05 (-50.00% YoY). Gross margin improved to 82.06% (+41.56% YoY), indicating better operational efficiency despite profitability challenges.
Analysts from BTIG and Piper Sandler recently lowered their price targets to $4 (from $5 and $6, respectively) while maintaining Buy/Overweight ratings. The adjustments reflect concerns over lower-than-expected revenue and inventory issues.
